Tenascin-R and C in multiple sclerosis lesions: Relevance to extracellular matrix remodelling

Neuropathology and Applied Neurobiology

Volumn 25, Issue 3, 1999, Pages 207-214

  Gutowski, N J ^a,b   Newcombe, J ^a   Cuzner, M L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

Author keywords

Extracellular matrix; Glial scar; Macrophages; Multiple sclerosis; Tenascin C; Tenascin R

Indexed keywords

BIOLOGICAL MARKER; TENASCIN;

ADULT; AGED; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MULTIPLE SCLEROSIS; NERVE FIBER; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMYELINIZATION; SCAR FORMATION; WHITE MATTER;

EID: 0032968168     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2990.1999.00176.x     Document Type: Article

References (38)

1. Bartsch S, Bartsch U, Dorries U et al. Expression of tenascin in the developing and adult cerebellar cortex. J Neurosci 1992; 12: 736-49
2. Bristow J, Tee MK, Gitelman SE et al. Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B. J Cell Biol 1993; 122: 265-78
3. Brodkey JA, Laywell ED, O'Brien TF et al. Focal brain injury and upregulation of a developmentally regulated extracellular matrix protein. J Neurosurg 1995; 82: 106-12
4. Carnemolla B, Leprini A, Borsi L et al. Human tenascin complete primary structure, pre-mRNA alternative splicing and gene localization on chromosome 1q23-24. J Biol Chem 1996; 271: 8157-60
5. Chiquet-Ehrismann R. Anti-adhesive molecules of the extracellular matrix. Curr Opin Cell Biol 1991; 3: 800-4
6. Crossin KL, Prieto AL, Hoffman S et al. Expression of adhesion molecules and the establishment of boundaries during embryonic and neural development. Exp Neurol 1990; 109: 6-18
7. Cuzner ML, Gveric D, Strand C et al. The expression of tissue-type plasminogen activator, matrix metalloproteinases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996; 55: 1194-209
8. Faissner A, Kruse J. J1/Tenascin is a repulsive substrate for central nervous system neurons. Neuron 1990; 5: 627-37
9. ffrench-Constant C, Miller RH, Burne JF et al. Evidence that migratory oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells are kept out of the rat retina by a barrier at the eye-end of the optic nerve. J Neurocytol 1988; 17: 13-25
10. Franklin RJM, Gilson JM, Blakemore WF. Local recruitment of remyelinating cells in the repair of demyelination in the central nervous system. J Neurosci Res 1997; 50: 337-44
11. Frost E, Kiernan BW, Faissner A et al. Regulation of oligodendrocyte precursor migration by extracellular matrix: evidence for substrate-specific inhibition of migration by tenascin-C. Dev Neurosci 1996; 18: 266-73
12. Grierson JP, Petroski RE, Ling DSF et al. Astrocyte topography and tenascin/cytostatin expression: correlation with the ability to support neuritic outgrowth. Brain Res Dev Brain Res 1990; 55: 11-9
13. Groves AK, Entwistle A, Jat PS et al. The characterization of astrocyte cell lines that display properties of glial scar tissue. Dev Biol 1993; 159: 87-104
14. Lassmann H, Bruck W, Lucchinetti C et al. Remyelination in multiple sclerosis. Mult Scler 1997; 3: 133-6
15. Laywell E, Dörries U, Bartsch U et al. Enhanced expression of the developmentally regulated extracellular matrix molecule tenascin following adult brain injury. Proc Natl Acad Sci USA 1992; 89: 2634-8
16. Leprini A, Querze G, Zardi L. Tenascin isoforms: possible targets for diagnosis and therapy of cancer and mechanisms regulating their expression. Perspectives Devel Neurobiol 1994; 2: 117-23
17. Li H, Newcombe J, Groome NP et al. Characterization and distribution of phagocytic macrophages in multiple sclerosis plaques. Neuropathol Appl Neurobiol 1993; 19: 214-33
18. Ludwin SK. Pathology of demyelination and remyelination. In Demyelinating Disease: Basic and Clinical Electrophysiology, Eds SG Waxman, JM Ritchie. New York: Raven Press, 1981: 123-68
19. Mahler M, Ferhat L, Ben-Ari Y et al. Effects of tenascin-C in cultured hippocampal astrocytes: NCAM and fibronectin immunoreactivity changes. Glia 1997; 20: 231-42
20. Murphy-Ullrich JE, Lightner VA, Aukhil I et al. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol 1991; 115: 1127-36
21. Natali PG, Nicotra MR, Bigotti A et al. Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. Int J Cancer 1991; 47: 811-6
22. Newcombe J, Cuzner ML. Monoclonal antibody 14E identifies the oligodendrocyte cell body in normal adult human and rat white matter. J Neuroimmunol 1988; 19: 11-20
23. Nies DE, Hemesath TJ, Kim J-H et al. The complete cDNA sequence of human hexabrachion (tenascin): a multidomain protein containing unique epidermal growth factor repeats. J Biol Chem 1991; 266: 2818-23
24. Perides G, Erickson HP, Rahemtulla F et al. Colocalization of tenascin with versican, a hyaluronate-binding chondroitin sulfate proteoglycan. Anat Embryol 1993; 188: 467-79
25. Pesheva P, Gloor S, Schachner M et al. Tenascin-R is an intrinsic autocrine factor for oligodendrocyte differentiation and promotes cell adhesion by a sulfatide-mediated mechanism. J Neurosci 1997; 17: 4642-51
26. Pesheva P, Spiess E, Schachner M. J-160 and J-180 are oligodendrocyte-secreted non-permissive substrates for cell adhesion. J Cell Biol 1989; 109: 1765-78
27. Prieto AL, Jones FS, Cunningham BA et al. Localisation during development of alternatively spliced forms of cytotactin mRNA by in situ hybridization. J Cell Biol 1990; 111: 685-98
28. Prineas JW, Kwon EE, Goldenberg PZ et al. Multiple sclerosis: oligodendrocyte proliferation and differentiation in fresh lesions. Lab Invest 1989; 61: 489-503
29. Raine CS, Scheinberg L, Waltz JM. Multiple sclerosis: oligodendrocyte survival and proliferation in active established lesions. Lab Invest 1981; 45: 534-46
30. Ranscht B, Clapshaw PA, Price J et al. Development of oligodendrocytes and Schwann cells studied with a monoclonal antibody against galactocerebroside. Proc Natl Acad Sci USA 1982; 79: 2709-13
31. Siri A, Carnemolla B, Saginati M et al. Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies. Nucl Acids Res 1991; 19: 525-31
32. Siri A, Knauper V, Veirana N et al. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem 1995; 270: 8650-4
33. Smith GM, Hale JH. Macrophage/microglia regulation of astrocytic tenascin: synergistic action of transforming growth factor-β and basic fibroblast growth factor. J Neurosci 1997; 17: 9624-33
34. Sobel RA. The extracellular matrix in multiple sclerosis lesions. J Neuropathol Exp Neurol 1998; 57: 205-17
35. Tucker RP, Brunso-Bechtold JK, Jenrath DA et al. Cellular origins of tenascin in the developing nervous system. Perspectives Devel Neurobiol 1994; 2: 89-99
36. Wintergerst ES, Bartsch U, Batini C et al. Changes in the expression of the extracellular matrix molecules tenascin-C and tenascin-R after 3-acetylpyridine-induced lesion of the olivocerebellar system of the adult rat. Eur J Neurosci 1997; 9: 424-34
37. Wintergerst ES, Fuss B, Bartsch U. Localization of janusin mRNA in the central nervous system of the developing adult mouse. Eur J Neurosci 1993; 5: 299-310
38. Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 1998; 18: 601-9